Charles W. Abbott

1000 total citations
33 papers, 398 citations indexed

About

Charles W. Abbott is a scholar working on Cancer Research, Molecular Biology and Oncology. According to data from OpenAlex, Charles W. Abbott has authored 33 papers receiving a total of 398 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Cancer Research, 14 papers in Molecular Biology and 12 papers in Oncology. Recurrent topics in Charles W. Abbott's work include Cancer Genomics and Diagnostics (16 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Molecular Biology Techniques and Applications (4 papers). Charles W. Abbott is often cited by papers focused on Cancer Genomics and Diagnostics (16 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Molecular Biology Techniques and Applications (4 papers). Charles W. Abbott collaborates with scholars based in United States, United Kingdom and Germany. Charles W. Abbott's co-authors include Kelly J. Huffman, M Snyder, Catherine A. Dye, Richard Chen, Rachel Marty Pyke, Melanie Ashland, Samuel M. Lancaster, Brittany Lee‐McMullen, Aaron Horning and Éric Levy and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Journal of Neuroscience.

In The Last Decade

Charles W. Abbott

28 papers receiving 390 citations

Peers

Countries citing papers authored by Charles W. Abbott

Since Specialization

Citations

This map shows the geographic impact of Charles W. Abbott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles W. Abbott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles W. Abbott more than expected).

Fields of papers citing papers by Charles W. Abbott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles W. Abbott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles W. Abbott. The network helps show where Charles W. Abbott may publish in the future.

Co-authorship network of co-authors of Charles W. Abbott

This figure shows the co-authorship network connecting the top 25 collaborators of Charles W. Abbott. A scholar is included among the top collaborators of Charles W. Abbott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles W. Abbott. Charles W. Abbott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Whole genome sequencing-powered ctDNA sequencing for breast cancer detection 2025 ·Annals of Oncology ·Isaac García-Murillas, Charles W. Abbott, Rosalind Cutts, (unknown), Jacqueline A. Pugh, Kathleen C. Keough, Bo Li, (unknown), Fábio C. P. Navarro, Richard Chen, (unknown), Catey Bunce, S. Johnston, Alexander Ring, Simon Russell, (unknown), A. Skene, I. E. Smith, (unknown)	10
2	Spatially Resolved, Multiregion Proteomics for Prediction of Immunotherapy Outcome in Deficient Mismatch Repair Metastatic Colorectal Cancer 2025 ·Clinical Cancer Research ·Bahar Saberzadeh-Ardestani, Zhenglong Liu, (unknown), (unknown), Christy E. Trussoni, Charles W. Abbott, Dongyao Yan, (unknown), Kandavel Shanmugam, Rondell P. Graham, Alos Diallo, Joshua Levy, Tamás Ördög, Frank A. Sinicrope	3
3	Identifying the optimal post-surgical timing of molecular residual disease (MRD) detection in colorectal cancer (CRC) using an ultra-sensitive assay: Interim results from the VICTORI study. 2025 ·Journal of Clinical Oncology ·(unknown), Emma Titmuss, Fábio C. P. Navarro, Charles W. Abbott, (unknown), James T. Topham, (unknown), (unknown), (unknown), Howard J. Lim, Karamjit S. Gill, Sharlene Gill, Carl J. Brown, (unknown), Adam Meneghetti, Daniel J. Renouf, David F. Schaeffer, (unknown), Sean Michael Boyle, Jonathan M. Loree	0
4	Prognostic and predictive value of ultrasensitive ctDNA monitoring in a metastatic pan-cancer cohort treated with immune checkpoint inhibitors in the context of phase 1 clinical trials. 2024 ·Journal of Clinical Oncology ·Rodrigo A. Toledo, (unknown), Oriol Mirallas, Ana Carolina Ramos Moreno, (unknown), Guzmán Alonso, María Vieito, Irene Braña, (unknown), (unknown), José Jiménez, (unknown), Cristina Viaplana, Raquel Pérez-López, Paolo Nucíforo, Charles W. Abbott, Jason R. Pugh, (unknown), Sean Michael Boyle, Elena Garralda	2
5	Ultra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in patients with early breast cancer. 2024 ·Journal of Clinical Oncology ·Isaac García-Murillas, Ros Cutts, Charles W. Abbott, Sean Michael Boyle, Jason R. Pugh, Richard Chen, (unknown), Catey Bunce, Stephen Johnston, Alistair Ring, Simon Russell, (unknown), Anthony Skene, Duncan Wheatley, Ian E. Smith, Nicholas C. Turner	8
6	Ultra-sensitive ctDNA dynamics to capture therapy response in pembrolizumab-treated gastroesophageal cancer. 2024 ·Journal of Clinical Oncology ·Andrew B. Nixon, Fábio C. P. Navarro, Katherine I. Zhou, Charles W. Abbott, Lauren E. Howard, John C. Brady, Yingmiao Liu, Jingquan Jia, Donna Niedzwiecki, Richard Chen, John H. Strickler, Sean Michael Boyle, Hope E. Uronis	1
7	Circulating tumor DNA (ctDNA) kinetics in colorectal cancer (CRC) treated with curative intent in the VICTORI study with an ultrasensitive MRD assay. 2024 ·Journal of Clinical Oncology ·(unknown), Emma Titmuss, Fábio C. P. Navarro, Charles W. Abbott, (unknown), James T. Topham, (unknown), (unknown), (unknown), Howard J. Lim, Karamjit S. Gill, Sharlene Gill, Carl J. Brown, (unknown), Adam Meneghetti, Daniel J. Renouf, David F. Schaeffer, (unknown), Sean Michael Boyle, Jonathan M. Loree	0
8	LBA55 An ultra-sensitive and specific ctDNA assay provides novel pre-operative disease stratification in early stage lung cancer 2023 ·Annals of Oncology ·James R. Black, Alexander M. Frankell, Selvaraju Veeriah, (unknown), Mark S. Hill, Charles W. Abbott, (unknown), Bo Li, Rui Chen, Maise Al Bakir, (unknown), Ariana Huebner, Mariam Jamal‐Hanjani, Nicholas McGranahan, Charles Swanton	6
9	Precision Neoantigen Discovery Using Large-Scale Immunopeptidomes and Composite Modeling of MHC Peptide Presentation 2023 ·Molecular & Cellular Proteomics ·Rachel Marty Pyke, (unknown), (unknown), Charles W. Abbott, (unknown), (unknown), Jason Harris, Gábor Bartha, Sejal Desai, (unknown), John West, M Snyder, Richard Chen, Sean Michael Boyle	14
10	Association of ultra-sensitive ctDNA assay to identify actionable variants and response to immune checkpoint inhibitor (ICI) therapy in metastatic melanoma. 2023 ·Journal of Clinical Oncology ·Christoffer Gebhardt, Laura Keller, Isabel Heidrich, (unknown), (unknown), Charles W. Abbott, Sean Michael Boyle, Jason R. Pugh, Richard Chen, Ronald Simon, Stefan W. Schneider, Klaus Pantel	1
11	A machine learning algorithm with subclonal sensitivity reveals widespread pan-cancer human leukocyte antigen loss of heterozygosity 2022 ·Nature Communications ·Rachel Marty Pyke, Dattatreya Mellacheruvu, (unknown), Charles W. Abbott, Lee McDaniel, Devayani P. Bhave, (unknown), Éric Levy, Gábor Bartha, John West, M Snyder, Richard Chen, Sean Michael Boyle	18
12	Global, distinctive, and personal changes in molecular and microbial profiles by specific fibers in humans 2022 ·Cell Host & Microbe ·Samuel M. Lancaster, Brittany Lee‐McMullen, Charles W. Abbott, Jeniffer Quijada, Daniel Hornburg, (unknown), Dalia Perelman, (unknown), Michael T. Tang, Aaron Robinson, Sara Ahadi, Kévin Contrepois, (unknown), Melanie Ashland, Tracey McLaughlin, (unknown), Aaron Horning, Justin L. Sonnenburg, M Snyder	80
13	Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms 2021 ·Clinical Cancer Research ·Charles W. Abbott, Sean M. Boyle, Rachel Marty Pyke, Lee McDaniel, Éric Levy, Fábio C. P. Navarro, Dattatreya Mellacheruvu, (unknown), Mengyao Tan, (unknown), (unknown), Pamela Milani, Gábor Bartha, Jason Harris, (unknown), M Snyder, Sekwon Jang, Richard Chen	35
14	Association of HLA loss of heterozygosity with allele-specific neoantigen expansion in response to immunotherapy. 2021 ·Journal of Clinical Oncology ·Rachel Marty Pyke, Charles W. Abbott, (unknown), (unknown), A. Dimitrios Colevas, Éric Levy, (unknown), M Snyder, (unknown), John B. Sunwoo, Richard Chen, Sean Michael Boyle	1
15	Candidate variants in TUB are associated with familial tremor 2020 ·PLoS Genetics ·M. Reza Sailani, Fereshteh Jahanbani, Charles W. Abbott, Hayan Lee, Amin Zia, Shannon Rego, Juliane Winkelmann, Franziska Hopfner, Tahir Naeem Khan, Nicholas Katsanis, Stefanie H. Müller, Daniela Berg, (unknown), Christian Mychajliw, Günther Deuschl, Jonathan A. Bernstein, Gregor Kuhlenbäumer, M Snyder	1
16	Rescue of ethanol-induced FASD-like phenotypes via prenatal co-administration of choline 2020 ·Neuropharmacology ·(unknown), Charles W. Abbott, Kelly J. Huffman	21
17	Rapid Changes in Cortical and Subcortical Brain Regions after Early Bilateral Enucleation in the Mouse 2015 ·PLoS ONE ·(unknown), Charles W. Abbott, Kelly J. Huffman	9
18	The effects of lifelong blindness on murine neuroanatomy and gene expression 2015 ·Frontiers in Aging Neuroscience ·Charles W. Abbott, (unknown), Kelly J. Huffman	9
19	Prenatal Ethanol Exposure Disrupts Intraneocortical Circuitry, Cortical Gene Expression, and Behavior in a Mouse Model of FASD 2013 ·Journal of Neuroscience ·(unknown), Charles W. Abbott, Kelly J. Huffman	52
20	Bilateral enucleation alters gene expression and intraneocortical connections in the mouse 2012 ·Neural Development ·Catherine A. Dye, Charles W. Abbott, Kelly J. Huffman	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact